Critical Care Diagnostics Market Size, Share & Trends Analysis Report By Type (Routine & Special Chemistry, Flow Cytometry, Hematology, Immunoproteins), By End Use (Operation Room, Intensive Care Unit, Emergency Rooms), By Region, And Segment Forecasts, 2

Critical Care Diagnostics Market Size, Share & Trends Analysis Report By Type (Routine & Special Chemistry, Flow Cytometry, Hematology, Immunoproteins), By End Use (Operation Room, Intensive Care Unit, Emergency Rooms), By Region, And Segment Forecasts, 2025 - 2030


Critical Care Diagnostics Market Growth & Trends

The global critical care diagnostics market size is expected to reach USD 2.10 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 6.11% from 2025 to 2030. The key factors supporting the industry’s growth comprise the rapid awareness and acknowledgment of these tests by physicians and patients, the rise in geriatric population and chronic health conditions, the employment of telehealth services in remote areas, and technological advancements. The increased cost of the molecular diagnostics and dearth of skilled labor are factors that are expected to hinder the growth of the industry.

The critical care diagnostics market by type is categorized into routine and special chemistry, flow cytometry, hematology, immunoproteins, microbial and infectious diseases, coagulation testing, and others. The microbial and infectious diseases test diagnostics segment is projected to grow at the highest rate with a CAGR of over 7.24% during the forecast period. For example, healthcare systems spend a substantial amount of resources in the collection and processing of blood cultures for the identification of pathogens.

Critical care diagnostic tests, such as the nucleic acid amplification test, allow clinicians to detect and identify organisms more rapidly and accurately and provide guidance to clinicians, who aspire to commence the appropriate antimicrobial therapy as fast as possible and terminate the use of avoidable drugs. The critical care diagnostic market by the end-user is categorized into operation rooms, emergency rooms, and ICU’s. The emergency rooms segment in the industry is anticipated to witness the highest growth rate during the forecast period.

Critical Care Diagnostics Market Report Highlights
  • The Asia Pacific region is expected to grow at the fastest CAGR of 8.0% during the forecast period. The large presence of geriatric population, increasing prevalence of chronic diseases, increase in the number of specialty hospitals in the Asia Pacific region, and improving healthcare services and infrastructures in rural areas are the factors fueling the market growth.
  • The immunoproteins diagnostic test segment is estimated to account for the largest share of the critical care diagnostic market by type. The rise in demand for rapid and accurate preventive healthcare services is one of the major factors driving this market growth.
  • On the basis of end-users, approximately 20% of acute-care patients get admitted into ICU’s, whereas nearly 58% get admitted into emergency rooms. The emergency rooms are expected to witness exponential growth with the highest CAGR during the forecast period. The recent rise in the patient demand for ER services is due to its ability to provide initial acute care diagnosis and treatment of critically ill patients.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.5. Market Restraint Analysis
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
Chapter 4. Type Business Analysis
4.1. Critical Care Diagnostics Market: Type Movement Analysis
4.2. Routine & Special Chemistry
4.2.1. Routine & Special Chemistry Market, 2018 - 2030 (USD Million)
4.3. Flow Cytometry
4.3.1. Flow Cytometry Market, 2018 - 2030 (USD Million)
4.4. Hematology
4.4.1. Hematology Market, 2018 - 2030 (USD Million)
4.5. Immunoproteins
4.5.1. Immunoproteins Market, 2018 - 2030 (USD Million)
4.6. Microbial & Infectious Disease
4.6.1. Microbial & Infectious Disease Market, 2018 - 2030 (USD Million)
4.7. Coagulation Testing
4.7.1. Coagulation Testing Market, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. End-use Business Analysis
5.1. Critical Care Diagnostics Market: End-use Movement Analysis
5.2. Operation Room
5.2.1. Operation Room Market, 2018 - 2030 (USD Million)
5.3. Intensive Care Unit
5.3.1. Intensive Care Unit Market, 2018 - 2030 (USD Million)
5.4. Emergency Rooms
5.4.1. Emergency Rooms Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Critical Care Diagnostics Market Share By Region, 2024 & 2030
6.2. North America
6.2.1. North America Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Competitive Scenario
6.2.2.4. Regulatory Framework
6.2.2.5. Reimbursement Scenario
6.2.2.6. U.S. Critical Care Diagnostics Market, 2018 - 2030 (USD MILLION)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. Canada Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.2.4. Mexico
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Reimbursement Scenario
6.2.4.6. Mexico Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Critical diagnostics Market, 2018 - 2030 (USD Million)
6.3.2. Germany
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Competitive Scenario
6.3.2.4. Regulatory Framework
6.3.2.5. Reimbursement Scenario
6.3.2.6. Germany Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.3.3. UK
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. UK Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. France Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. Italy Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Reimbursement Scenario
6.3.6.6. Spain Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Reimbursement Scenario
6.3.7.6. Denmark Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Reimbursement Scenario
6.3.8.6. Sweden Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Reimbursement Scenario
6.3.9.6. Norway Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Competitive Scenario
6.4.2.4. Regulatory Framework
6.4.2.5. Reimbursement Scenario
6.4.2.6. Japan Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. China Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. India Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.4.5. South Korea
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. Reimbursement Scenario
6.4.5.6. South Korea Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.4.6. Australia
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Reimbursement Scenario
6.4.6.6. Australia Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Reimbursement Scenario
6.4.7.6. Thailand Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Competitive Scenario
6.5.2.4. Regulatory Framework
6.5.2.5. Reimbursement Scenario
6.5.2.6. Brazil Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. Argentina Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA Critical diagnostics Market, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Competitive Scenario
6.6.2.4. Regulatory Framework
6.6.2.5. Reimbursement Scenario
6.6.2.6. South Africa Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. Saudi Arabia Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. UAE Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. Kuwait Critical Care Diagnostics Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Share Analysis, 2024
7.4. Company Profiles/Listing
7.4.1. Abbott
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Collection Site Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Danaher
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Collection Site Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Siemens Healthineers
7.4.3.1. Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Collection Site Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. F. Hoffmann-La Roche Ltd.
7.4.4.1. Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Collection Site Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Quidel Corporation
7.4.5.1. Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Collection Site Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. bioMérieux S.A
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Collection Site Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Chembio Diagnostics, Inc.
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Collection Site Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. EKF Diagnostics
7.4.8.1. Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Collection Site Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Bayer AG
7.4.9.1. Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Collection Site Benchmarking
7.4.9.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings